<DOC>
	<DOC>NCT01037062</DOC>
	<brief_summary>To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy</brief_summary>
	<brief_title>An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects who completed a previous entecavir Phase II studies (AI463047, 052 or 053); ALT ≤ 10 x upper limit of normal; Subjects must have wellcompensated liver disease according to ALL of the following criteria; 1. Prothrombin time ≤ 3 seconds prolonged compared to control value or INR ≤ 1.5 2. Serum albumin ≥ 3 g/dL (≥ 30 g/L) 3. Serum bilirubin ≤ 2.5 mg/dL (≤ 42.75 μmol/L) Sex and Reproductive Status Exceptions Target Disease Exceptions Medical History and Concurrent Diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>